Honeywell Aerospace Dossier
|
SectorIndustrials IndustryAerospace & Defense Beta (adjusted)1.00 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $154.07Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $48.8B Enterprise Value $63.6B Shares Outstanding 317M diluted Next Earnings Date4 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Honeywell Aerospace began independent trading on June 29, 2026 with a broad installed base, recurring aftermarket exposure and strong demand indicators. Second-quarter backlog reached $18.154 billion, up 9% year over year, while trailing-twelve-month orders rose 8%. However, supply constraints limited output, adjusted EBIT declined 7%, and management reduced 2026 organic-growth guidance from 7%-9% to 4%-5% and adjusted-EBIT guidance from $4.65-$4.75 billion to $4.35-$4.45 billion. The resulting balance of durable demand and elevated execution risk supports a Hold pending evidence that supplier actions restore output and stabilize profitability. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$175.00 Mean target$225.31 High · most bullish analyst$306.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $175.0020% Supply constraints, unfavorable mix and higher costs persist, causing organic growth or adjusted EBIT to fall below revised guidance. Weak conversion of the demand backlog and continued separation-related disruption delay the expected operational recovery. Base CaseCentral scenario $225.3156% Matches the consensus meanDemand remains healthy, supported by backlog and aftermarket activity, while supply constraints improve only gradually. Full-year organic growth and adjusted EBIT remain within the revised guidance ranges, with progress toward stronger execution in 2027. Bull CaseUpside scenario $306.0024% Supplier qualification, additional tooling and expanded multi-sourcing improve output during the second half. Backlog converts efficiently, organic growth reaches the top of the 4%-5% range, and adjusted EBIT reaches the upper end of $4.35-$4.45 billion. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |